EP 4362970 A1 20240508 - MONOMERIC FUSION PEPTIDES AND METHOD OF USE THEREOF
Title (en)
MONOMERIC FUSION PEPTIDES AND METHOD OF USE THEREOF
Title (de)
MONOMERE FUSIONSPEPTIDE UND VERFAHREN ZUR VERWENDUNG DAVON
Title (fr)
PEPTIDES DE FUSION MONOMÈRES ET LEUR MÉTHODE D'UTILISATION
Publication
Application
Priority
- US 202163216688 P 20210630
- US 2022035699 W 20220630
Abstract (en)
[origin: WO2023278683A1] A fusion peptide comprising a GLP1 variant, and at least one adiponectin agonist peptide which is chemically attached to the GLP1 variant via by a spacer. The GLP1 variant portion can include one or more substitutions relative to the native GLP1. The adiponectin agonist peptide can be attached to the GLP1 variant at different attachment sites. A method of treating a metabolic disorder or condition using the fusion peptide is also provided.
IPC 8 full level
A61K 38/26 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61K 38/27 (2006.01); C07K 1/00 (2006.01)
CPC (source: EP IL KR US)
A61K 47/64 (2017.08 - EP IL US); A61P 3/10 (2018.01 - EP IL KR US); C07K 7/06 (2013.01 - KR); C07K 14/5759 (2013.01 - EP IL); C07K 14/605 (2013.01 - EP IL KR US); A61K 38/00 (2013.01 - KR); C07K 2319/00 (2013.01 - EP IL KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2023278683 A1 20230105; AU 2022304682 A1 20240104; CA 3224490 A1 20230105; CN 117750969 A 20240322; EP 4362970 A1 20240508; IL 309655 A 20240201; JP 2024524431 A 20240705; KR 20240047956 A 20240412; TW 202307010 A 20230216; US 2023021946 A1 20230126
DOCDB simple family (application)
US 2022035699 W 20220630; AU 2022304682 A 20220630; CA 3224490 A 20220630; CN 202280046622 A 20220630; EP 22834208 A 20220630; IL 30965523 A 20231224; JP 2023580787 A 20220630; KR 20237044996 A 20220630; TW 111124534 A 20220630; US 202217854594 A 20220630